GNNSF Stock - Genscript Biotech Corporation
Unlock GoAI Insights for GNNSF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $594.49M | $839.53M | $625.70M | $511.06M | $390.85M |
| Gross Profit | $272.13M | $409.55M | $304.08M | $282.52M | $255.89M |
| Gross Margin | 45.8% | 48.8% | 48.6% | 55.3% | 65.5% |
| Operating Income | $9.28M | $-415,791,000 | $-436,038,000 | $-368,313,590 | $-204,546,000 |
| Net Income | $2.96B | $-95,477,000 | $-226,851,000 | $-358,712,000 | $-204,945,000 |
| Net Margin | 498.2% | -11.4% | -36.3% | -70.2% | -52.4% |
| EPS | $1.40 | $-0.05 | $-0.11 | $-0.18 | $-0.11 |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
GNNSFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | — | — | — | — |
Q3 2025 | Aug 17, 2025 | $0.08 | $-0.01 | -114.8% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.01 | $1.44 | +14500.0% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.01 | $-0.08 | -727.3% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.05 | $-0.00 | +98.2% | ✓ BEAT |
Q2 2023 | Jun 29, 2023 | — | $-0.04 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.05 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.06 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.12 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.05 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.06 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.04 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.01 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.01 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.01 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.01 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.01 | — | — |
Latest News
Frequently Asked Questions about GNNSF
What is GNNSF's current stock price?
What is the analyst price target for GNNSF?
What sector is Genscript Biotech Corporation in?
What is GNNSF's market cap?
Does GNNSF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GNNSF for comparison